Ilorasertib

Drug Profile

Ilorasertib

Alternative Names: A-968660.0; Abbott-968660; ABT-348

Latest Information Update: 09 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; National Cancer Institute (USA); University of Chicago
  • Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Platelet-derived growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 05 Jun 2017 Pooled pharmacokinetics/pharmacodynamics analysis of two phase I trials in Solid tumours (Late-stage disease, Metastatic disease) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Aug 2016 Phase-II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in USA (PO) (NCT02478320)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top